Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 14 and
  • 15
Journal for ImmunoTherapy of Cancer20197:73

https://doi.org/10.1186/s40425-019-0559-3

  • Received: 8 March 2019
  • Accepted: 8 March 2019
  • Published:

The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:109

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:109

https://doi.org/10.1186/s40425-018-0420-0

Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable.” should be replaced with “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable.” (3.0% instead of 0.3%).

The publisher apologizes for any inconvenience caused by this error.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, Charlotte, NC 28204, USA
(2)
Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
(3)
Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14203, USA
(4)
Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
(5)
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA
(6)
Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA 02215, USA
(7)
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
(8)
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
(9)
Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
(10)
Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, T2N 4N2, Canada
(11)
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, M5G 1Z5, Canada
(12)
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
(13)
Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G 1Z2, Canada
(14)
Oncology - Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ 08541, USA
(15)
Department of Internal Medicine, UT Southwestern – Kidney Cancer Program, Dallas, TX 75390, USA

Reference

  1. Amin A, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109. https://doi.org/10.1186/s40425-018-0420-0.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement